Targeted Neuronal Injury for the Non-Invasive Disconnection of Brain Circuitry
September 27th, 2020
4.7K views
The goal of the protocol is to provide a method for producing non-invasive neuronal lesions in the brain. The method utilizes Magnetic Resonance-guided Focused Ultrasound (MRgFUS) to open the Blood Brain Barrier in a transient and focal manner, in order to deliver a circulating neurotoxin to the brain parenchyma.
Overview
This study presents a non-invasive method for producing focal neuronal lesions in the brain, utilizing Magnetic Resonance-guided Focused Ultrasound (MRgFUS). By transiently opening the blood-brain barrier, a neurotoxin is delivered to targeted regions, enabling precise neuronal loss without damaging surrounding tissues.
Key Study Components
Area of Science
- Neuroscience
- Non-invasive surgical techniques
- Neuronal lesioning
Background
- Current surgical interventions for neurological diseases can be invasive and damaging to non-target tissues.
- A non-invasive technique for producing neuronal lesions is sought to enhance treatment options.
- The study explores the Ping method, which focuses on precisely targeting neuronal loss.
- This method involves opening the blood-brain barrier and delivering a neurotoxin systemically.
Purpose of Study
- To demonstrate a non-invasive approach for creating neuronal lesions in targeted brain areas.
- To utilize MRgFUS for focal blood-brain barrier openings.
- To assess the effectiveness and specificity of the neurotoxin delivery.
Methods Used
- Magnetic Resonance-guided Focused Ultrasound (MRgFUS) was employed.
- Animal models, specifically the tish rat, were used to target cortical malformations.
- The method includes a series of steps: animal preparation, administration of microbubbles, sonication, and infusion of quinolinic acid.
- Histological analysis was performed post-euthanasia to evaluate neuronal degeneration.
Main Results
- The Ping method successfully produced neuronal loss localized to the areas where the blood-brain barrier was opened.
- Fluoro Jade staining indicated numerous degenerating neurons within targeted regions.
- Focused ultrasound followed by neurotoxin administration demonstrated precise targeting capabilities.
- Post-mortem analyses revealed the effectiveness of the method in achieving its goals.
Conclusions
- This study provides evidence for a non-invasive surgical technique to selectively induce neuronal lesions.
- The methodology demonstrated the potential to enhance therapeutic strategies for neurological disorders.
- Insights gained could advance the understanding of neuronal mechanisms and treatment paradigms.
Frequently Asked Questions
What advantages does the Ping method offer?
The Ping method is non-invasive, reducing the risk of injury to non-target tissues while enabling precise neuronal targeting.
How is the neurotoxin administered in this method?
The neurotoxin is delivered systemically after the blood-brain barrier is opened using MRgFUS, allowing targeted access to brain parenchyma.
What types of outcomes does this study analyze?
The study assesses neuronal degeneration and lesion specificity using histological techniques such as Fluoro Jade staining.
Can this method be applied to other neurological disorders?
Yes, the Ping technique can be adapted for various neurological conditions that require targeted neuronal loss or lesioning.
What are the critical steps in the procedure?
Important steps include animal preparation, targeted sonication, and post-sonication neurotoxin infusion followed by histological analysis.
What limitations should be considered with this method?
Potential limitations include the need for specialized equipment and expertise in MRgFUS and careful monitoring to avoid off-target effects.
Executive Industry Relevance
Non-invasive neuronal lesioning addresses a critical gap in preclinical neuroscience by enabling precise circuit interrogation without surgical trauma. This capability supports target validation and mechanistic de-risking in neurological drug discovery, particularly for disorders involving maladaptive circuitry such as epilepsy and movement disorders. By restricting neuronal loss to defined brain regions, the method enhances predictive confidence in early-stage target hypothesis testing.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by selectively disrupting defined neuronal pathways to assess functional consequences.
- Operational Value: Provides a reproducible, non-invasive means to lesion specific brain targets, reducing variability associated with surgical approaches.
- Predictive Confidence: Supports target de-risking by establishing causal links between neuronal circuit modulation and phenotypic outcomes in disease models.
Screening & Assay Development
- Scientific Value: Generates quantifiable, histologically confirmed neuronal loss as a functional readout for target engagement and pathway modulation.
- Operational Value: Enables standardized lesion generation across studies, supporting assay reproducibility and cross-laboratory consistency.
- Scalability: Compatible with rodent models, allowing integration into high-content screening workflows for neuroactive compound evaluation.
Translational & Preclinical Research
- Disease-Relevant System: Applied in genetic models of cortical malformation (e.g., tish rat) to mimic human neurological pathologies involving aberrant circuitry.
- Translational Continuity: Bridges discovery and preclinical stages by enabling circuit-level interventions that mirror clinical neuromodulation or ablation strategies.
- Mechanistic De-risking: Clarifies whether observed phenotypes depend on specific neuronal populations, reducing ambiguity in target mechanism interpretation.
Pipeline & Workflow Integration
The method fits within the discovery-to-preclinical continuum, supporting early target hypothesis testing through precise circuit disruption prior to lead optimization and mechanistic validation.
- Discovery Biology: Facilitates causal testing of neuronal targets in disease-relevant circuits, enabling hypothesis-driven target validation.
- Screening: Produces standardized, quantifiable lesion phenotypes suitable for screening neuroprotective or neuromodulatory compounds.
- Analytics: Relies on MRI-confirmed blood-brain barrier opening and histological quantification of neuronal degeneration as key decision-point outputs.
- Translational Research: Models interventions analogous to clinical neuromodulation, supporting extrapolation to human circuit-based therapies.
- Enterprise Reuse: Establishes a reusable platform for circuit interrogation across multiple neuroscience projects and target classes.
Operational & Enterprise Impact
- Scientific Value: Enhances target validation confidence by enabling precise, reversible circuit dissection without confounding surgical injury.
- Operational Value: Standardizes lesion generation via image-guided targeting and systemic neurotoxin delivery, improving inter-study reproducibility.
- Strategic Value: Informs go/no-go decisions by clarifying target necessity and sufficiency in disease models, reducing late-stage attrition.
- Portfolio Impact: Supports risk-adjusted prioritization of targets based on circuit-level functional validation.
Implementation Considerations
- Requires expertise in MR-guided focused ultrasound operation and neurotoxin handling protocols.
- Depends on MRI-compatible focused ultrasound systems and contrast-enhanced imaging for target validation.
- Necessitates standardized procedures for microbubble and quinolinic acid delivery across study sites.
- Must account for species-specific blood-brain barrier permeability and neurotoxin dosing parameters.
- Limited to applications where focal, irreversible neuronal loss is an acceptable experimental endpoint.
Biopharma FAQs
Why does confirming blood-brain barrier opening matter for target validation?
Confirming blood-brain barrier opening via contrast-enhanced T1-weighted imaging ensures that the neurotoxin reaches only the intended brain region, which is essential for attributing observed neuronal loss to the targeted circuit and supporting causal target validation.
How does isolating the independent variable (focused ultrasound targeting) fit the discovery pipeline?
Isolating focused ultrasound as the independent variable allows researchers to attribute neuronal loss specifically to the targeted brain region, enabling precise circuit interrogation in early-stage target hypothesis testing and de-risking.
What quantitative dependent variable measurements enable mechanistic de-risking?
Quantitative histological measurements such as Fluoro Jade staining of degenerating neurons provide objective, replicable readouts of lesion extent, enabling assessment of target engagement and mechanistic specificity in preclinical studies.
Why do replication requirements matter for cross-functional collaboration?
Replication requirements ensure that lesion generation is consistent across experiments and laboratories, which is critical for reliable data sharing between discovery, preclinical, and translational teams in multi-site neuroscience programs.
What statistical analysis capabilities are required before implementation?
Implementation requires statistical capabilities to compare neuronal loss between targeted and control regions, as well as to evaluate lesion specificity using post-sonication imaging and histological quantification to support go/no-go decisions.
Chapters in this video
0:00
Introduction
1:36
Animal Preparation
2:44
PING Procedure
5:55
MRI/FUS Control Room
6:35
Targeting of FUS
7:07
Administration of Microbubble, FUS, and Contrast Age
7:47
Infusion of Quinolinic Acid
8:15
Results: Imaging and Microscopy
10:03
Conclusions for PING Method
